MedTrace Logo

A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

NCT05919069 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2026-05-11

No results posted yet for this study

Summary

Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment

Conditions

  • Hepatic Impairment

Interventions

DRUG

AZD2693

Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-16
Primary Completion
2024-09-16
Completion
2024-09-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05919069 on ClinicalTrials.gov